# First-in-human Dose Escalation and Expansion Study With the SIRPα-directed Monoclonal Antibody BYON4228

> **NCT05737628** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Byondis B.V.** · enrollment: 17 (actual)

## Conditions studied

- Lymphoma

## Interventions

- **DRUG:** BYON4228 + Rituximab

## Key facts

- **NCT ID:** NCT05737628
- **Lead sponsor:** Byondis B.V.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-03-04
- **Primary completion:** 2026-02
- **Final completion:** 2026-05
- **Target enrollment:** 17 (ACTUAL)
- **Last updated:** 2026-01-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05737628

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05737628, "First-in-human Dose Escalation and Expansion Study With the SIRPα-directed Monoclonal Antibody BYON4228". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT05737628. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*